News

ASP0113 is an investigational vaccine candidate under development for the prevention of CMV disease and associated complications in transplant recipients. Vical licensed the vaccine, ASP0113, to Astellas Pharma

Moberg Pharma’s distribution agreement with the Menarini Group – a top 40 global pharmaceutical company – includes Italy, China and eight countries in Southeast Asia. In addition to

Neurodegenerative diseases, such as Alzheimer’s disease (AD), Hutchinson’s Disease, Parkinson’s disease, Kuru, Creutzfeldt-Jakob disease and other spongiform encephalopathies remain major health problems. Currently there are very limited means

NPC-1C targets a unique member of the MUC family that is specific to colorectal cancer with little reactivity to normal cells. Encouraging overall survival (OS) data was observed

SignalRx was awarded a Phase 1 Small Business Technology Transfer Research (STTR) grant from the National Cancer Institute (NCI), a division of the National Institutes of Health (NIH),

"We are very pleased to announce that the FDA has provided these two important designations to our Sanfilippo drug candidates, reflecting their potential to address the significant unmet

ImmunoClin will be responsible for managing and coordinating all aspects of the clinical trial on behalf of Celtic including protocol preparation, monitoring, project management, and regulatory reporting. Spotlight

The company said that this next Phase IIa dose expansion trial is a multicenter, randomized, open-label, controlled study, which is expected to be completed in the fourth quarter

VTU Technology currently offers a very broad and comprehensive Pichia pastoris expression platform and the deal grants Biomay access to VTU’s Pichia pastoris protein expression technology. Under the